Conference Coverage
Conference Coverage
Daratumumab Quadruplet Supported Transplant-Ineligible MM
A phase-3 study showed that adding daratumumab to VRd yields a primary endpoint of MRD negativity in patients newly diagnosed with myeloma.
Conference Coverage
Myeloma: Daratumumab Plus Lenalidomide Improves MRD Outcomes
New research shows that adding daratumumab to maintenance therapy improves MRD and PFS outcomes in multiple myeloma.
Conference Coverage
Sex and Gender Influence Outcomes in Colorectal Cancer
Sex differences have clear biological and pathophysiological consequences in oncology.
Latest News
Melanoma: Neoadjuvant Immunotherapy Provides Optimal Survival Results
Those who received combination therapy achieved higher event- and recurrence-free survival than patients who received monotherapy.
Latest News
Identifying Drug-Induced Rashes in Skin of Color: Heightened Awareness Can Accelerate Diagnosis
In patients with DIHS and many of the even more serious types of rashes traced to drug exposures, the delay to appearance of the rash from the...
Latest News
FDA Initiative Aims to Improve Diversity in Clinical Trials
This initiative could be a critical step toward ensuring diversity in major clinical trials after years of stagnation, Dr. Valerie Harvey said.
Conference Coverage
Osimertinib/Savolitinib Combo Shows Promise in NSCLC
Can combining two agents overcome MET-driven primary resistance in MET-aberrant, EGFR-mutated advanced NSCLC?
Conference Coverage
No Matched Sibling Donor? Sickle Cell Experts Debate Next-Best Option
SCD specialists differ on the best treatment choices for patients who lack an available matched sibling donor.
Conference Coverage
Treatment Options in MCL: What Are the Best Practices?
Experts on mantle cell lymphoma share findings on how best to treat patients at various ages and stages.
Conference Coverage
Debate: Should CAR T Best Be Used in Early MM Relapse?
When patients with myeloma relapse, blood cancer specialists disagree on whether and when to treat them with CAR T-cell therapy.
Conference Coverage
A Simple Blood Test May Predict Cancer Risk in T2D
Can the markers of inflammation IL-6, tumor necrosis factor alpha (TNF-alpha), and high-sensitivity C-reactive protein (hsCRP) be predictive...